<DOC>
	<DOCNO>NCT00445822</DOCNO>
	<brief_summary>Newly diagnose pediatric patient ( age &lt; 19 year ) bcr-abl-positive CML treat imatinib . Serial monitoring treatment response perform one month interval first three month treatment three month interval thereafter . Patients non-response , poor response ( either molecular , cytogenetic , hematologic non-/poor response ) progress disease imatinib treatment stop imatinib undergo stem cell transplantation . All responder imatinib treatment HLA match donor undergo stem cell transplantation later 2 year diagnosis .</brief_summary>
	<brief_title>Registration Children With CML Treatment With Imatinib</brief_title>
	<detailed_description>Indication : Newly diagnose pediatric patient bcr-abl-positive CML . Design : Multicenter , non-randomized , open , prospective clinical trial . Objectives : Primary : - assessment antileukemic activity imatinib child adolescent Philadelphia chromosome-positive chronic myeloid leukemia Secondary : - assessment time-to event-efficacy variable - correlation quality haematological , cytogenetical molecular remission child adolescent CML ongoing imatinib therapy survival - safety imatinib Endpoints : Primary : - rate haematological , cytogenetical molecular remission Secondary : - time progression - duration chronic phase - time loss response - overall survival - assessment treatment-related toxicity child adolescent . Inclusion criterion : Newly diagnose Ph+ bcr-abl-positive CML- Male female patient age 0 18 years- Written inform consent Exclusion criterion : - CML without bcr-abl rearrangement detectable PCR - Pretreatment Interferon alpha cytostatic drug exception hydroxyurea anagrelide ( Note : anagrelide approve Germany treatment CML ) . However , patient may register observational patient . - Any severe underlying disease beside CML . - Age &gt; 18 year - Pregnant lactate woman - Subjects unlikely comply requirement protocol Number patient enrol : 150 Recruitment period : 5 year Treatment period : 2 year Planned start study : 2007 Planned end study : 2013</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Newly diagnose Ph+ bcrablpositive CML Male female patient age 0 18 year Written inform consent CML without bcrabl rearrangement detectable PCR Pretreatment Interferon alpha cytostatic drug exception hydroxyurea anagrelide ( Note : anagrelide approve Germany treatment CML ) . However , patient may register observational patient . Any severe underlying disease beside CML . Age &gt; 18 year Pregnant lactating woman Subjects unlikely comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>CML</keyword>
	<keyword>Children</keyword>
	<keyword>Imatinib</keyword>
	<keyword>bcr-abl</keyword>
	<keyword>Response</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>